Veradigm Ends Business Review Process on Lack of Final Bids

Like
Comment
Favorite

Veradigm Ends Business Review Process on Lack of Final Bids

Dow Jones01-31

By Sabela Ojea

Veradigm is ending its review of strategic alternatives for the company almost eight months after the process began.

The healthcare technology company on Thursday said that while five bidders submitted preliminary, non-binding indications of interest, it didn't receive any final proposals.

Last May, the company said its board of directors had initiated a process to evaluate alternatives for the company and maximize value for shareholders.

"After engaging with over 30 parties, the board has unanimously decided to end the strategic review," Chairman Greg Garrison said. "However, we remain open to all opportunities that enhance stockholder value."

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

January 30, 2025 18:28 ET (23:28 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2507350602?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-31 07:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507350602","market":"hk","top_or_hot":-1,"title":"Veradigm Ends Business Review Process on Lack of Final Bids","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Veradigm is ending its review of strategic alternatives for the company almost eight months after the process began. \n</p>\n<p>\n  The healthcare technology company on Thursday said that while five bidders submitted preliminary, non-binding indications of interest, it didn't receive any final proposals. \n</p>\n<p>\n  Last May, the company said its board of directors had initiated a process to evaluate alternatives for the company and maximize value for shareholders. \n</p>\n<p>\n  \"After engaging with over 30 parties, the board has unanimously decided to end the strategic review,\" Chairman Greg Garrison said. \"However, we remain open to all opportunities that enhance stockholder value.\" \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 30, 2025 18:28 ET (23:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veradigm Ends Business Review Process on Lack of Final Bids</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeradigm Ends Business Review Process on Lack of Final Bids\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-31 07:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Veradigm is ending its review of strategic alternatives for the company almost eight months after the process began. \n</p>\n<p>\n  The healthcare technology company on Thursday said that while five bidders submitted preliminary, non-binding indications of interest, it didn't receive any final proposals. \n</p>\n<p>\n  Last May, the company said its board of directors had initiated a process to evaluate alternatives for the company and maximize value for shareholders. \n</p>\n<p>\n  \"After engaging with over 30 parties, the board has unanimously decided to end the strategic review,\" Chairman Greg Garrison said. \"However, we remain open to all opportunities that enhance stockholder value.\" \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 30, 2025 18:28 ET (23:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4167","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2507350602","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507350602","pubTimestamp":1738279680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Veradigm is ending its review of strategic alternatives for the company almost eight months after the process began.The healthcare technology company on Thursday said that while five bidders submitted preliminary, non-binding indications of interest, it didn't receive any final proposals.Last May, the company said its board of directors had initiated a process to evaluate alternatives for the company and maximize value for shareholders.\"After engaging with over 30 parties, the board has unanimously decided to end the strategic review,\" Chairman Greg Garrison said. \"However, we remain open to all opportunities that enhance stockholder value.\"","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4167":"医疗保健技术","MDRX":"麦赛斯医药"},"translate_title":"Veradigm因缺乏最终投标而结束业务审查流程","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDRX":0.9},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Veradigm is ending its review of strategic alternatives for the company almost eight months after the process began. \n\n\n  The healthcare technology company on Thursday said that while five bidders submitted preliminary, non-binding indications of interest, it didn't receive any final proposals. \n\n\n  Last May, the company said its board of directors had initiated a process to evaluate alternatives for the company and maximize value for shareholders. \n\n\n  \"After engaging with over 30 parties, the board has unanimously decided to end the strategic review,\" Chairman Greg Garrison said. \"However, we remain open to all opportunities that enhance stockholder value.\" \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2025 18:28 ET (23:28 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}